



# Proteomics International

LABORATORIES LTD

ASX Release  
4 February 2022

ASX code: PIQ

## Unique panel of biomarkers identified for oesophageal cancer

- Proteomics International has identified and validated a panel of protein biomarkers with potential to test for oesophageal adenocarcinoma, the most common oesophageal cancer
- Research is part of a collaboration with QIMR Berghofer to develop a novel diagnostic test
- Biomarkers validated in a study of more than 300 patients
- Collaboration is part of Proteomics International's strategy to continually expand its diagnostics portfolio in areas of significant unmet medical need

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to announce it has successfully completed its validation study with QIMR Berghofer Medical Research Institute (QIMR Berghofer) targeting oesophageal adenocarcinoma, the most common form of oesophageal cancer in Australia.

Proteomics International and QIMR Berghofer are collaborating on the development of a simple blood test for oesophageal adenocarcinoma [ASX: 9 October 2020], using a panel of biomarkers - protein 'fingerprints' in the blood - initially identified by QIMR Berghofer researchers. The analysis sought to demonstrate the robustness of the biomarkers across laboratories through a series of analytical and clinical validation experiments, building upon Proteomics International's experience acquired in developing the PromarkerD assay, the world's first test for predicting diabetic kidney disease.

Proteomics International managing director Dr Richard Lipscombe said the research studied multiple proteins in the blood associated with early-stage oesophageal adenocarcinoma. *"From these, we've been able to identify a select panel of biomarkers with the potential to be used as a diagnostic test. Importantly we have also completed validation of the panel using blood samples from more than 300 patients."*

The results of the study will be presented today at the 27th Lorne Proteomics Symposium, Victoria, the annual conference of the Australasian Proteomics Society (see copy of presentation attached, titled: *Translational Proteomics: Establishing a Mass Spectrometry Assay for Biomarkers of Oesophageal Cancer*). The results showed several protein biomarkers (N=5-7) were statistically significant in identifying oesophageal adenocarcinoma.

The study focused on Barrett's oesophagus, a pre-malignant condition that is a major risk factor for oesophageal adenocarcinoma. Barrett's oesophagus affects about 2% of the population<sup>1</sup> and occurs when the oesophagus is damaged by acid reflux<sup>2</sup>. These patients are currently screened using invasive and costly endoscopy procedures.

Proteomics International and QIMR Berghofer will now finalise arrangements for the future development of the biomarkers into a diagnostic test for oesophageal cancer.

<sup>1</sup> Barrett's oesophagus: epidemiology, diagnosis and clinical management (2016); doi.org/10.5694/mja16.00796

<sup>2</sup> American Society for Gastrointestinal Endoscopy, www.asge.org

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

**About QIMR Berghofer ([www.qimrberghofer.edu.au](http://www.qimrberghofer.edu.au))**

QIMR Berghofer Medical Research Institute was established by the Queensland Government 75 years ago and has a rich history of scientific discoveries and translational medical research. QIMR Berghofer is focused on improving health by developing new diagnostics and better treatments and prevention strategies, specifically in the areas of cancer, infectious diseases, mental health and chronic disorders. The Institute works in close collaboration with clinicians and other research institutes and is home to approximately 1000 scientists, students and support staff. QIMR Berghofer has an active program for the commercialisation of technologies, including those developed in conjunction with academic or commercial collaborators.

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

e-Poster


| February 3<sup>rd</sup> – 6<sup>th</sup> 2022

## Translational Proteomics: Establishing a Mass Spectrometry Assay for Biomarkers of Oesophageal Cancer

**Marisa N. Duong**<sup>1</sup>, Scott Bringans<sup>1</sup>, Michelle M. Hill<sup>2</sup>,  
Connor Laming<sup>1</sup>, Richard J. Lipscombe<sup>1</sup>

1. *Proteomics International, Nedlands, WA, Australia*


2. *QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia*




# Disease Background

## Barrett's esophagus (BE)

## Oesophageal adenocarcinoma (OAC)



# Technology Transfer




Glycoprotein capture from  
serum & on-bead digestion

correlate with the presence of  
early stage OAC.



- ✓ Method transfer and optimisation
- ✓ Automated workflow  
10 h → 5 h
- ✓ Converted to Microflow LCMS  
0.4 mL/min → 5 µL/min  
50 min → 20 min


## Method transfer and optimisation



✓ Jacalin is the lectin of choice

✓ Robust:

- 4 sample replicates over 3 days 33 peptides
- Average intraday CV is 9.3%
- Average interday CV is 11.5%



# Cohort 1 (Oschner cohort) (n = 50)

Protein	Trend (i.e. OAC compared to healthy)	
	<i>QIMRB</i>	<i>PI</i>
<b>Haptoglobin</b>	Not significant	↑
<b>Alpha-1-antitrypsin</b>	Not significant	↑
<b>Alpha-1-antichymotrypsin</b>	↑	↑
<b>Complement component C9</b>	↑	↑
<b>Gelsolin</b>	↓	↓
<b>Plasma kallikrein</b>	↓	Not significant
<b>Serum paraoxonase/ arylesterase</b>	↓	↓



↑ or ↓ indicates p value <0.05

# Cohort 2 (PROBENET cohort) (n=266)

Protein	Trend (i.e. OAC compared to healthy)	
	<i>QIMRB</i>	<i>PI</i>
<b>Haptoglobin</b>	↑	↑
<b>Alpha-1-antitrypsin</b>	↑	↑
<b>Complement component C9</b>	↑	↑
<b>Gelsolin</b>	↓	↓
<b>Plasma kallikrein</b>	↓	↓
<b>Serum paraoxonase/ arylesterase</b>	↓	↓
<b>Beta-2-glycoprotein</b>	↑	Not significant

↑ or ↓ indicates p value <0.05

# Example proteins and peptides



- ✓ Robust method transferred
- ✓ Panels of glycoproteins as potential diagnostic biomarkers for OAC

